This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Aspirin Exacerbated Respiratory Disease Market

Market Insights on Aspirin Exacerbated Respiratory Disease covering sales outlook, demand forecast & up-to-date key trends

Aspirin Exacerbated Respiratory Disease Market by Product Type, Distribution Channel, Route of Administration & Region - Forecast 2022 - 2032

Aspirin Exacerbated Respiratory Disease Market

The global aspirin exacerbated respiratory disease market size is expected to reach US$ 8.7 Billion in 2032 and exhibit growth at a CAGR of 4.9% in the forecast period from 2022 to 2032. As per the report, sales of treatment options for aspirin exacerbated respiratory disease is likely to exceed US$ 3.1 Billion in 2022. The increasing number of research and development activities to discover novel treatment options are anticipated to boost the market.

Report Attribute

Details

Aspirin Exacerbated Respiratory Disease Market Estimated Base Year Value (2021)

US$ 2.5 Billion

Aspirin Exacerbated Respiratory Disease Market Expected Market Value (2022)

US$ 3.1 Billion

Aspirin Exacerbated Respiratory Disease Market Anticipated Forecast Value (2032)

US$ 8.7 Billion

Aspirin Exacerbated Respiratory Disease Market Projected Growth Rate (2022-2032)

4.9% CAGR

Aspirin-exacerbated respiratory disease or Samter’s Triad is a chronic medical condition that includes three clinical features, namely, sensitivity to aspirin, sinus disease with recurrent nasal polyps, and asthma. Signs and symptoms of this disease do not usually show up until an individual reaches their 30s or 40s.

Some of the signs and symptoms include sneezing, difficulty breathing, runny nose, coughing, or wheezing. Some people living with aspirin-exacerbated respiratory disease often get these types of reactions if they drink alcoholic beverages, such as wine or beer.

There is no specific test to diagnose the disease. Laboratory tests, such as blood tests help in looking for higher than normal levels of eosinophils, which are white blood cells. Healthcare professionals often recommend urine tests to observe inflammatory substances and elevated leukotrienes in the body.

Is Prevalence of Asthma Influencing the Aspirin Exacerbated Respiratory Disease Market

Increasing prevalence of breathing problems, such as asthma is anticipated to augur well for the global market. As per the World Health Organization (WHO), nearly 262 million people were living with asthma in 2019 and it had caused 461000 deaths. These numbers are projected to grow at a fast pace, thereby pushing the demand for aspirin exacerbated respiratory disease treatment options.

Moreover, surging awareness programs conducted by government agencies to educate the masses about the signs and symptoms of this disease is set to drive the market. Rising healthcare expenditure in both developed and developing countries across the globe is another vital factor that is likely to fuel the market.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which Are Some of the Hindrances to the Aspirin Exacerbated Respiratory Disease Market

The diagnosis of aspirin exacerbated respiratory disease can often be delayed unless healthcare professionals have experience or expertise in recognizing and treating it. Thus, the lack of skilled healthcare professionals across emerging economies is projected to hamper the aspirin exacerbated respiratory disease market growth in future years.

What is the North America Aspirin Exacerbated Respiratory Disease Market Outlook

North America is likely to remain at the forefront by procuring the largest aspirin exacerbated respiratory disease market share in the upcoming years. The presence of numerous large-scale pharmaceutical companies in the U.S. and Canada is projected to augur well for the regional market.

The increasing consumption of zileuton (Zyflo) or montelukast (Singulair) to block the effects of leukotrienes across North America is also set to propel the market. In addition to that, patients are increasingly adopting medications, such as inhaled corticosteroids to manage asthma and it is further expected to augment the market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is the Asia Pacific Aspirin Exacerbated Respiratory Disease Market Progressing

Asia Pacific is likely to remain in the second position followed by North America in terms of share during the evaluation period. Rising prevalence of pollution induced asthma and the ongoing development of healthcare infrastructure in China and India are anticipated to drive the sales of aspirin exacerbated respiratory disease treatment medications.

Besides, the entry of international pharmaceutical companies in these countries owing to the availability of low-cost labor and raw material is expected to foster growth. The availability of innovative injectable medications, commonly called biologics, would also contribute to the regional market growth.

Market Competition

Some of the renowned companies operating in the global aspirin exacerbated respiratory disease market include Apotex Corporation, Pfizer Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Cadila Pharmaceuticals among others.

Majority of the leading companies present in the global market are increasingly focusing on mergers and acquisitions, collaborations, and joint ventures to co-develop novel products and strengthen their positions. Meanwhile, a few other key players are aiming to invest huge sums for conducting clinical trials to develop state-of-the-art medications.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Scope of Report

Report Attribute

Details

Growth Rate

CAGR of 4.9% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2015-2020

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Product Type
  • Distribution Channel
  • Route of Administration
  • Region

Regions Covered

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

  • Apotex Corporation
  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Zydus Pharmaceuticals
  • Cadila Pharmaceuticals

Customization

Available Upon Request

Key Segments Profiled in the Aspirin Exacerbated Respiratory Disease Industry Survey

By Product Type:

  • Glucocorticoids
  • Antihistamines
  • Aspirin Desensitization

Route of Administration:

  • Nasal
  • Oral

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Stores
  • Online Pharmacy

By Region:

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • Asia Pacific Excluding Japan and China
  • China
  • Japan
  • Middle East & Africa

Frequently Asked Questions

The global aspirin exacerbated respiratory disease market is projected to exceed US$ 8.7 Billion in 2032.

North America is expected to dominate the aspirin exacerbated respiratory disease market in the near future.

Apotex Corporation, Pfizer Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Cadila Pharmaceuticals are some of the leading companies in the aspirin exacerbated respiratory disease market.

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Hirschsprung Disease Treatment Market

Published : September 2017

Healthcare

Gastroesophageal Reflux Disease Therapeutics Market

Published : April 2016

Healthcare

Fabry Disease Market

Published : April 2016

Healthcare

Infectious Disease Diagnostics Market

Published : January 2016

Google translate

Aspirin Exacerbated Respiratory Disease Market